ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2664

Increased Risk of Hematological Malignancies in Children Born to Women with SLE

Evelyne Vinet1, Ann E. Clarke2, Christian A. Pineau3, Susan Scott4, Robert W. Platt5 and Sasha Bernatsky6, 1McGill University Health Center, Montreal, QC, Canada, 2Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 3Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Malignancy, pediatrics and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose

Patients with SLE have an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, compared to the general population. Recently, in utero exposures, such as chronic maternal autoimmune conditions, have been associated with the development of childhood hematological malignancies. However, until now, no one has assessed the risk of hematological cancers in children born to women with SLE. Thus, in a large population-based study, we aimed to determine if SLE offspring have an increased risk of hematological malignancies, versus controls.

Methods

The “Offspring of SLE mothers Registry (OSLER)” includes all women who had ≥1 hospitalization for delivery after SLE diagnosis, identified through Quebec’s universal healthcare databases (1989-2009). OSLER also includes a randomly selected control group of women, matched at least 4:1 for age and year of delivery, who did not have a diagnosis of SLE prior to or at the time of delivery. We identified children born live to SLE mothers and their matched controls, and ascertained hematological malignancies based on ≥1 hospitalization or physician visit with a relevant diagnostic code, through to end of database follow-up.

We performed multivariate logistic regression analyses, using generalized estimating equations, to adjust for maternal demographics and comorbidities, sex of child, and gestational diabetes. In a subsample analysis of children with maternal drug coverage throughout pregnancy, we further assessed relevant in utero medication exposures.

Results

509 women with SLE had 719 children, while 5824 matched controls had 8493 children. Mean maternal age and follow-up were respectively 30.3 (SD 5.0) and 9.1 (SD 5.8) years. Children born to women with SLE experienced more hematological malignancies (9/719) compared to controls (38/8493) [1.25% (95% CI 0.61, 2.45) versus 0.45% (95% CI 0.32, 0.62), difference 0.80% (95% CI 0.14, 2.01)]. The most frequent type of hematological cancer in both groups was acute lymphoblastic leukemia. Of note, primary non-Hodgkin lymphoma of bone was observed in 2/719 SLE offspring as opposed to 6/8493 control children [0.28% (95% CI 0.05, 1.12) versus 0.07% (95% CI 0.01, 0.16), difference 0.21% (95% CI -0.04, 1.05)]. In multivariate analyses (n=9212), children born to women with SLE appeared to have an increased risk of hematological cancers versus controls (OR 2.80, 95% CI 1.33, 5.92).

In the subsample of children with drug coverage (n=1925), in utero medication exposures were rare in the 10 hematological cancer cases: none was exposed to antimalarials, corticosteroids, or immunosuppressants.

Conclusion

Our data suggest that compared to children from the general population, children born to women with SLE may have an increased risk of hematological malignancies. However, it must be emphasized that this outcome is extremely rare, and our findings remain to be confirmed by other study methods. The lack of association with in utero drug exposures may be viewed as somewhat re-assuring, though this too is preliminary.


Disclosure:

E. Vinet,
None;

A. E. Clarke,
None;

C. A. Pineau,
None;

S. Scott,
None;

R. W. Platt,
None;

S. Bernatsky,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-hematological-malignancies-in-children-born-to-women-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology